# Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

> **NCT02610868** · PHASE3 · COMPLETED · sponsor: **Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC** · enrollment: 187 (actual)

## Conditions studied

- Sialorrhea

## Interventions

- **DRUG:** MYOBLOC

## Key facts

- **NCT ID:** NCT02610868
- **Lead sponsor:** Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02610868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02610868, "Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02610868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*